2012 Fiscal Year Final Research Report
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
| Project/Area Number |
22590157
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
MATZNO Sumio 近畿大学, 薬学部, 教授 (30299094)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUYAMA Kenji 近畿大学, 薬学部, 教授 (00117251)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 臨床薬学 / 第2世代抗精神病薬 / メタボリック症候群 / レプチン / 細胞分化 |
|---|
| Research Abstract |
In this study, the authors evaluated the effect of atypical antipsychotic agents (SGAs) on metabolic syndrome induction. Using neuroblastoma cell lines, one of SGAs, olanzapine, induced 5HT_<2C> mRNA transcription in PC12 autonomic neuroblastoma. Furthermore, olanzapine also induced PPAR_γ translation and subsequent fat accumulation in 3T3L1 mouse adipoblastoma cell line. These results suggest that olanzapine induces metabolic syndrome by synergistic effect of both an activation of sympathetic nervous system and an elevation of direct differentiation of adipose tissues.
|
